October 9, 2023

Meeta Gulyani joins the Novo Holdings Advisory Group

Novo Holdings is pleased to announce the appointment of Meeta Gulyani to the Novo Advisory Group (NAG), an expert panel of senior industry leaders that supports Novo Holdings in analysing and monitoring its larger life science investments.

Kasim Kutay, CEO of Novo Holdings, said: “With her extensive market knowledge and executive experience in the pharmaceutical and life science industries, Meeta brings valuable insights to our Advisory Group’s work. I am delighted to welcome Meeta on board and very much look forward to her contributions.”

Meeta Gulyani has over two and half decades of international experience working with business-wide strategic development and implementation, driving large-scale transformation and delivering strong operating performance. In her most recent position for Millipore Sigma, the Life Science Division of Merck KGaA, Darmstadt, Germany, she was responsible for the organisation’s long-term strategy, business development and sustainability agenda. In addition, following the USD 17 Billion acquisition of the chemical giant Sigma-Aldrich, she led its successful integration. Meeta was previously the Head of Strategy and Global Franchises for the Biopharma business of Merck KGaA, Darmstadt, Germany.

Before joining Merck KGaA, Darmstadt Germany in 2014, Meeta served as General Manager for Roche South Asia, and Vice President, Head of Global Portfolio Management at Roche. In addition, she has held several marketing and sales leadership positions within Sanofi and served as a strategy consultant with the Monitor Consulting Group based in Hong Kong and the United States.

Meeta Gulyani said: “It’s an honour for me to join the Novo Advisory Group. I look forward to being able to draw on my industry experience and contribute to Novo Holdings’ important mission of generating attractive financial returns to improve people’s health and the sustainability of society and the planet.”

About Meeta Gulyani
US citizen

Board and Executive positions
Since December 2021, Meeta has served on the Board of Directors of Seer, a life sciences company commercialising a disruptive new platform for proteomics. For the Life Science business of Merck, KGaA, Darmstadt, Germany, she was a member of the Executive and Deal Review Committees and also chaired the M Ventures Life Science board, the company’s strategic, corporate venture capital arm. She additionally held executive leadership positions at the Biopharma division of Merck KGaA, Darmstadt Germany and at Roche Pharma.

Corporate Career
2016 – 2023    Executive VP, Head of Strategy, Business Development & Sustainability, Millipore Sigma (Life Science division of Merck KGaA, Darmstadt, Germany)

2014 – 2015     Executive VP, Head of Global Strategy & Franchises, EMD Serono (Biopharma division of Merck KGaA. Darmstadt, Germany)

2012 – 2014     General Manager, South Asia, Pharmaceuticals Division, Roche

2010 – 2011      VP, Head of Global Portfolio Management/Chief of Staff to Roche Pharma CEO, Pharmaceuticals Division, Roche

2002 – 2010    Various marketing and sales leadership positions at Sanofi (previously Sanofi-Aventis)

1996 – 2001     Senior Project Leader, Monitor Company (Hong Kong, US)

Meeta holds a Bachelor’s degree in Economics from the Shri Ram College of Commerce at Delhi University in India and a Post Graduate diploma in Apparel Marketing and Merchandising from the National Institute of Fashion Technology, India. In addition, she holds a Master of Business Administration from Asian Institute of Management, Philippines, accompanied by an exchange program at the Wharton School of the University of Pennsylvania.

Further information

Nils Eskestad, Senior Communications Manager, +45 3023 2904,